Global Glioblastoma Multiforme Treatment Market Report and Forecast 2024-2032

Glioblastoma Multiforme Treatment Market Report and Forecast 2024-2032


Glioblastoma Multiforme Treatment Market Outlook

The glioblastoma multiforme treatment market was valued at USD 2.5 billion in 2023, driven by the increasing incidence of brain cancer. The market size is anticipated to grow at a CAGR of 8.4% for the forecast period of 2024-2032 to achieve a value of USD 5.2 billion by 2032.

Glioblastoma Multiforme: Introduction

Glioblastoma multiforme (GBM) is an aggressive and malignant type of brain tumour that originates from the glial cells, which are supportive cells in the central nervous system. It is the most common and deadliest primary brain tumour in adults. GBM is characterized by its rapid growth, infiltrative nature, and resistance to treatment.

GBM typically occurs in adults and has a poor prognosis. It tends to progress rapidly and infiltrate surrounding brain tissue, making it challenging to treat. The exact cause of GBM is unknown, although certain risk factors such as genetic mutations, exposure to radiation, and a family history of brain tumors may increase the risk of developing the disease. Symptoms of GBM can vary depending on the location of the tumor within the brain. Common symptoms include headaches, seizures, cognitive impairment, changes in personality or behavior, weakness or numbness in the limbs, and difficulties with speech and coordination.

Key Trends in the Glioblastoma Multiforme Treatment Market

Several key trends are shaping the glioblastoma multiforme (GBM) treatment market:
  • Advancements in Targeted Therapies: Targeted therapies are designed to specifically target cancer cells based on their genetic mutations or specific molecular markers. In recent years, there have been significant advancements in targeted therapies for GBM, including drugs that target specific genetic mutations such as EGFRvIII and IDH1.
  • Immunotherapy Approaches: Immunotherapy has emerged as a promising treatment approach in various cancers, including GBM. Immunotherapies, such as immune checkpoint inhibitors and cancer vaccines, aim to enhance the body's immune response against cancer cells.
  • Combination Therapies: GBM treatment is increasingly moving towards combination therapies, where multiple treatment modalities are used together to improve treatment outcomes. This includes combining surgery with radiation therapy and chemotherapy, as well as combining traditional treatments with targeted therapies or immunotherapies.
  • Advancements in Surgical Techniques: Surgical resection plays a crucial role in the management of GBM. Advancements in surgical techniques, such as fluorescence-guided surgery and awake craniotomy, are enabling more precise tumor removal while minimizing damage to surrounding healthy brain tissue.
Glioblastoma Multiforme Treatment Market Segmentations

The market can be categorised into therapy, end user, and region.

Market Breakup by Therapy
  • Chemotherapy
  • Radiation Therapy
  • Other Treatments
Market Breakup by End user
  • Hospitals
  • Ambulatory Services
Market Breakup by Region -7MM
  • United States
  • EU-4 and the United Kingdom
  • Japan
Glioblastoma Multiforme Treatment Market Overview

Glioblastoma multiforme (GBM) is a highly aggressive and malignant form of brain cancer. It is characterized by rapid tumor growth, invasive behavior, and high resistance to treatment. The treatment of GBM usually involves a combination of surgery, radiation therapy, and chemotherapy. The market for GBM treatment is driven by the increasing incidence of brain cancer, including GBM, across the globe. The aging population, exposure to environmental factors, and genetic predisposition are some of the factors contributing to the rising incidence of GBM. Additionally, advancements in diagnostic techniques and increased awareness about brain cancer have led to early detection and diagnosis of GBM, further propelling the market growth.

In recent years, there have been significant efforts to develop innovative treatment approaches for GBM. These include targeted therapies, immunotherapies, and personalized medicine approaches. Targeted therapies focus on specific molecular targets present in GBM cells, aiming to inhibit their growth and survival. Immunotherapies harness the body's immune system to recognize and attack cancer cells. Personalized medicine involves tailoring treatment based on the individual patient's genetic profile and tumor characteristics. The GBM treatment market is highly competitive, with several pharmaceutical companies and research institutions actively involved in drug development and clinical trials. Additionally, collaborations between academic institutions, government organizations, and private companies play a crucial role in advancing GBM treatment options.

Key Players in the Glioblastoma Multiforme Treatment Market

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the Glioblastoma Multiforme Treatment market are as follows:
  • Arbor Pharmaceuticals
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Merck & Co. Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Lanthen Pharmaceutical
  • Pfizer Inc.
  • Amgen Inc.
  • Teva Pharmaceutical Industries Ltd.
We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Glioblastoma Multiforme Treatment Market Overview
3.1 Global Glioblastoma Multiforme Treatment Market Historical Value (2017-2023)
3.2 Global Glioblastoma Multiforme Treatment Market Forecast Value (2024-2032)
4 Global Glioblastoma Multiforme Treatment Market Landscape
4.1 Global Glioblastoma Multiforme Treatment: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Glioblastoma Multiforme Treatment: Product Landscape
4.2.1 Analysis by Drugs
4.2.2 Analysis by Therapy
5 Global Glioblastoma Multiforme Treatment Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Glioblastoma Multiforme Treatment Market Segmentation
6.1 Global Glioblastoma Multiforme Treatment Market by Therapy
6.1.1 Market Overview
6.1.2 Chemotherapy
6.1.3 Radiation Therapy
6.1.4 Other Treatments
6.2 Global Glioblastoma Multiforme Treatment Market by End User
6.2.1 Market Overview
6.2.2 Hospitals
6.2.3 Ambulatory Services
6.3 Global Glioblastoma Multiforme Treatment Market by Region
6.3.1 Market Overview
6.3.2 North America
6.3.3 Europe
6.3.4 Asia Pacific
6.3.5 Latin America
6.3.6 Middle East and Africa
7 North America Glioblastoma Multiforme Treatment Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Glioblastoma Multiforme Treatment Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Glioblastoma Multiforme Treatment Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Glioblastoma Multiforme Treatment Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Glioblastoma Multiforme Treatment Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Regulatory Framework
12.1 Regulatory Overview
12.1.1 US FDA
12.1.2 EU EMA
12.1.3 INDIA CDSCO
12.1.4 JAPAN PMDA
12.1.5 Others
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by NIH Departments
14.7 Analysis by Recipient Organization
15 Clinical Trials Analysis
15.1 Analysis by Trial Registration Year
15.2 Analysis by Trial Status
15.3 Analysis by Trial Phase
15.4 Analysis by Therapeutic Area
15.5 Analysis by Geography
16 Funding and Investment Analysis
16.1 Analysis by Funding Instances
16.2 Analysis by Type of Funding
16.3 Analysis by Funding Amount
16.4 Analysis by Leading Players
16.5 Analysis by Leading Investors
16.6 Analysis by Geography
17 Partnership and Collaborations Analysis
17.1 Analysis by Partnership Instances
17.2 Analysis by Type of Partnership
17.3 Analysis by Leading Players
17.4 Analysis by Geography
18 Supplier Landscape
18.1 Arbor Pharmaceuticals
18.1.1 Financial Analysis
18.1.2 Product Portfolio
18.1.3 Demographic Reach and Achievements
18.1.4 Mergers and Acquisitions
18.1.5 Certifications
18.2 Bristol-Myers Squibb
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Mergers and Acquisitions
18.2.5 Certifications
18.3 Eli Lilly and Company
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Mergers and Acquisitions
18.3.5 Certifications
18.4 F. Hoffmann-La Roche Ltd
18.4.1 Financial Analysis
18.4.2 Product Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Mergers and Acquisitions
18.4.5 Certifications
18.5 Merck & Co. Inc.
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Mergers and Acquisitions
18.5.5 Certifications
18.6 Sun Pharmaceutical Industries Ltd.
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Mergers and Acquisitions
18.6.5 Certifications
18.7 Lanthen Pharmaceutical
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Mergers and Acquisitions
18.7.5 Certifications
18.8 Pfizer Inc.
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Mergers and Acquisitions
18.8.5 Certifications
18.9 Amgen Inc.
18.9.1 Financial Analysis
18.9.2 Product Portfolio
18.9.3 Demographic Reach and Achievements
18.9.4 Mergers and Acquisitions
18.9.5 Certifications
18.10 Teva Pharmaceutical Industries Ltd.
18.10.1 Financial Analysis
18.10.2 Product Portfolio
18.10.3 Demographic Reach and Achievements
18.10.4 Mergers and Acquisitions
18.10.5 Certifications
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings